

Challenging Cases

RESOLUTE Trial	81.7% B2/C Lesions
	15.49 ±6.23 mm Lesion Length
	99.2% Device Success
	96.2% Procedure Success

Robust Clinical Trial Program*	RESOLUTE (130 patients)	CE Mark Trial 9-month results released at PCR 2007
	RESOLUTE II (~345 patients)	Angiographic Trial
	RESOLUTE III (~2000 patients)	International Trial
	RESOLUTE IV (~1900 patients)	Pivotal Trial
	RESOLUTE Small (~125 patients)	Small vessel
	RESOLUTE Long (~100 patients)	Long lesion
	RESOLUTE Large (~100 patients)	Large vessel

*Scheduled to commence enrollment subject to regulatory approval.

Designed to treat patients at higher clinical risk of TLR.

Proven components

- Sprint delivery system
- Modular Driver stent
- Zotarolimus drug



Innovative technologies

- BioLinx polymer system
- Complete endothelial healing
- Inhibition of neointimal growth

Positive clinical* and angiographic† results

- Low TLR
- Low stent thrombosis
- 0.22 mm in-stent late loss

*RESOLUTE trial, 129 patients at 9 months.
†RESOLUTE trial, 96 patients at 9 months.




ENDEAVOR Resolute RX Ordering Information

Contact your Medtronic sales representative

DIAMETER (mm)	LENGTH (mm)							
	8	9	12	14	15	18	24	30
2.25	ERES22508X	–	ERES22512X	ERES22514X	–	ERES22518X	ERES22524X	ERES22530X
2.50	ERES25008X	–	ERES25012X	ERES25014X	–	ERES25018X	ERES25024X	ERES25030X
2.75	ERES27508X	–	ERES27512X	ERES27514X	–	ERES27518X	ERES27524X	ERES27530X
3.00	–	ERES30009X	ERES30012X	–	ERES30015X	ERES30018X	ERES30024X	ERES30030X
3.50	–	ERES35009X	ERES35012X	–	ERES35015X	ERES35018X	ERES35024X	ERES35030X
4.00	–	ERES40009X	ERES40012X	–	ERES40015X	ERES40018X	ERES40024X	ERES40030X


ENDEAVOR RESOLUTE RX PRODUCT CODE



Technical Information

Minimum guide catheter I.D.
1.42 mm (≥ 5 F/0.056 in.)

Crossing profile mm (in.)
2.25–4.00 mm = 1.01–1.22 mm (0.040–0.048 in.)



*1.02 mm (3.0 F) for all 4.00 mm stent sizes

Medtronic CardioVascular
3576 Unocal Place
Santa Rosa, CA 95403
USA
Tel: +1 707 525 0111
www.Medtronic.com

Medtronic BV
Earl Bakkenstraat 10
6422 PJ Heerlen
The Netherlands
Tel: +31 45 566 8000
Fax: +31 45 566 8668



For distribution only in markets where Endeavor Resolute has been approved.
Not for distribution in the USA. © 2007 Medtronic, Inc. All rights reserved. Printed in the Netherlands. UC200801435EE 9/07



Endeavor Resolute

Medtronic Coronary Stent System
Design For Life

Expanding Treatment Options

Zotarolimus-Eluting Coronary Stent System

Do
current-generation
drug-eluting stents
(DES) meet the
needs of all of your
patients?

Unmet Needs

ADDRESSING CHALLENGING PATIENT GROUPS
SMALL VESSELS
9.3% MACE at 8 months—SES-SMART, Ardissino, *JAMA*, December 8, 2004
14.2% TLR at 12 months—TAXUS V Trial, Ellis, TCT 2005
MULTIVESSEL DISEASE*
14.3% TLR—The Milan DES Experience, Colombo, ACC 2004
DIABETICS*
11.3% MACE at 9 months—DIABETES Trial, Sabaté, TCT 2004
10.9% TLR at 12 months—TAXUS V Trial, Ellis, TCT 2005

Ideal Solution


DES requirements for more challenging cases:

- Highly deliverable stent platform to navigate tortuous anatomies
- Biocompatible polymer that allows for endothelial healing
- Effective drug-release kinetics that inhibit neointimal growth
- Positive clinical and angiographic outcomes

*The Endeavor Resolute stent is not indicated for the specific uses of multivessel disease and diabetes.

Proven Components


The Endeavor Resolute stent combines **proven DES components** with **innovative technologies** to treat patients at higher clinical risk of TLR.



Sprint Delivery System

*Outstanding low-profile advantage:**


- *FasTrac tip for easier crossing*
- *Soft Fulcrum balloon for greater flexibility*
- *Enhanced shaft with increased pushability*



Driver Stent

Uniform vessel support:

- *Advanced cobalt alloy*
- *Unique modular design*



Zotarolimus Drug


Inhibition of neointimal growth:

- *Highly lipophilic*
- *Noncytotoxic*

*Compared with XIENCE V, TAXUS Liberte and CYPHER SELECT Plus stents. Data on file at Medtronic, Inc.

Innovative Technologies


The Endeavor Resolute stent system introduces Medtronic's proprietary BioLinx polymer system.




Hydrophilic

- Hydrophilic properties allow for biocompatibility and endothelial healing.


Biocompatibility



Endothelial Healing



Endeavor Resolute




Endeavor

28-day results in porcine models.
Data on file at Medtronic, Inc.


Hydrophobic

- Hydrophobic properties allow for extended delivery of zotarolimus drug and significant inhibition of neointimal growth.


Extended Drug-Elution Kinetics




Inhibition of Neointimal Growth




BMS Control



28-day results in porcine models. Carter *et al.*, TCT 2006.



Endeavor Resolute



Clinical Trial Results

Positive clinical and angiographic outcomes.*

*Differentiated Clinical
Performance*

Low **TLR**

Low **Stent Thrombosis**

*Powerful Neointimal
Inhibition*

0.22 mm **In-stent
Late Loss**


*RESOLUTE clinical trial data from 129 patients at 9 months released at PCR 2007.

Endeavor Resolute

Medtronic Coronary Stent System
Design For Life

Two Complementary DES Polymers Designed to Treat a Broad Range of Patients

The Hydrophilic Properties of the BioLinx and PC Polymers Demonstrate a Low Potential for Inflammation



Severity of Inflammation Is Determined by the Number of Stent Struts with Surrounding Inflammatory Cells*

What is an inflammation score?

An inflammation score of 1 or less is highly desirable.


- 0 = 3 or fewer struts with 10 or fewer inflammatory cells surrounding the struts
- 1 = 3 to 6 struts with 10 or fewer inflammatory cells surrounding the struts
- 2 = Greater than 6 but less than 50% of the struts with 10 or fewer inflammatory cells surrounding the struts
- 3 = Greater than 10 inflammatory cells surrounding 50% or more struts




*Schwartz RS *et al.*, *Circulation*, 2004; 110:2498-2505.

Two Biocompatible DES Polymers with Unique Characteristics

The Hydrophobic Properties of BioLinx Polymer Allow for Extended Elution of Zotarolimus*



Extended Drug Elution Produces Long-Term, Controlled Tissue Exposure to Zotarolimus*



Medtronic CardioVascular
3576 Unocal Place
Santa Rosa, CA 95403
USA
Tel: +1 707 525 0111

www.Medtronic.com

Medtronic BV
Earl Bakkenstraat 10
6422 PJ Heerlen
The Netherlands
Tel: +31 45 566 8000
Fax: +31 45 566 8668